Benchmark Grants Stock Options

Vancouver, British Columbia--(Newsfile Corp. - November 7, 2017) - Benchmark Botanics Inc. (CSE: BBT) (formerly Kaiyue International Inc.) (the "Company" or "Benchmark") announces the granting of stock options to directors and officers of the Company for an aggregate of 8,700,000 stock options of the Company exercisable at C$0.20, being the unit price for each common share of the most recent private placement closed on November 2, 2017, effective November 7, 2017. The Options shall expire and terminate on November 6, 2022.

These stock options have been granted in accordance with the Company's Stock Option Plan. Pursuant to this plan, the Company is authorized to grant an aggregate of up to 10% of its issued and outstanding common shares on a rolling basis. Immediately following this award of stock options the Company has issued and outstanding stock options for 8,794,456 common shares of the Company and there were 4,624,230 stock options of the Company available for future grant.

ON BEHALF OF THE BOARD
BENCHMARK BOTANICS INC.

/s/ "Ping (Johnson) Zhang"
Ping (Johnson) Zhang
Chief Executive Officer

For further information contact:
Johnson Zhang
Chief Executive Officer
604.375.8218

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

Forward-Looking Statements This news release contains forward-looking statements pertaining to various risks and uncertainties regarding future events. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the business and future objectives of the Company. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including related to: (i) the facility and Potanicals' operations; (ii) adverse market conditions; (iii) the ability of the Company to complete financings in the future; (iv) dependence on suppliers and skilled labour; (v) government regulation and compliance with the ACMPR; (vi) managing and maintaining growth; (vii) unfavourable publicity or consumer perception litigation; and (viii) competition. The Company is not currently producing medical marijuana. There is a risk that Potanicals' Producer's License will not be amended to permit the Company to sell medical marijuana produced at its facility. Actual results could differ materially from those currently anticipated due to a number of factors and risks including the risk factors discussed in this news release and in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com and on the CSE website. These statements speak only as of the date of this news release. Except as required by law, the Company does not intend to update these forward-looking statements.